Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund - Growth

Add To Compare

previously known as Reliance Pharma Gr until

NAV on December 10, 2025
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 8,459 cr
Turnover Ratio 14.27%
Expense Ratio 1.80%
Exit Load 1.00%if redeemed within
1 Months
0.00%if redeemed after 1 Months
Returns
  • 1M: -0.89%
  • 1Y: -0.99%
  • 3M: -1.44%
  • 3Y: 21.06%
  • 6M: -0.97%
  • 5Y: 15.67%
Min Investment 5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since over 20 years) Kinjal Desai (Since over 7 years) Lokesh Maru (Since 3 months) Divya Sharma (Since 3 months)
ISIN INF204K01968
Fund Family Nippon
P/E Ratio 36.22
P/B Ratio 5.77
Launch Date June 05, 2004
Benchmark BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs BSE Healthcare TR INR

Alpha -1.11
Beta 0.91
R-Squared 94.80
Info Ratio -0.77
Tracking Err 3.74
Sortino 1.622
Sharpe 0.919
Std Dev 15.229
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

View Factsheet

-


Other plans of Nippon India Pharma


Other Equity funds by Nippon